UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: July 2021 (Report No. 3)
Commission File Number: 001-40303
Inspira Technologies Oxy B.H.N. Ltd.
(Translation of registrant’s name into English)
2 Ha-Tidhar St.
Ra’anana 4366504, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
CONTENTS
On July 19, 2021, Inspira Technologies Oxy B.H.N. Ltd., or the registrant, issued a press release titled “Inspira Technologies and Ben-Gurion University Have Developed a Platform Designed to Prevent Blood Clotting in Inspira’s ART System”, a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Inspira Technologies Oxy B.H.N. Ltd. |
| | | |
| Date: July 19, 2021 | By: | /s/ Dagi Ben-Noon |
| | | Name: | Dagi Ben-Noon |
| | | Title: | Chief Executive Officer |
2
